Besag, Frank MC

Chan, Adrienne YL

Hayes, Joseph F

Hsia, Yingfen

Jani, Yoghini H

Lai, Edward CC

Lau, Wallis CY

Man, Kenneth KC

Osborn, David PJ

Taxis, Katja

Tsai, Daniel HT

Wei, Li

Wong, Ian CK

Yuen, Andrew SC

Recent studies raised concerns about the increasing use of gabapentinoids in different countries. With their potential for misuse and addiction, understanding the global consumption of gabapentinoids will offer us a platform to examine the need for any interventional policies. This longitudinal trend study utilised pharmaceutical sales data from 65 countries and regions across the world to evaluate the global trends in gabapentinoid consumption between 2008-2018. The multinational average annual percentage change of gabapentinoid consumption was +17.20%, increased from 4.17 defined daily dose per ten thousand inhabitants per day (DDD/TID) in 2008 to 18.26 DDD/TID in 2018. High-income countries had the highest pooled gabapentinoid consumption rate (39.92 DDD/TID) in 2018, which was more than six times higher than the lower-middle income countries (6.11 DDD/TID). The study shows that despite differences in healthcare system and culture, a consistent increase in gabapentinoid consumption is observed worldwide, with high-income countries remaining the largest consumers

UCL Discovery

English

Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study

https://discovery.ucl.ac.uk/id/eprint/10172716/

Gabapentinoid consumption in 65 countries and regions from 2008 to 2018 a longitudinal trend study

Gabapentinoid consumption in 65 countries and regions from 2008 to 2018 a longitudinal trend study

Abstract

Similar works

Full text

Available Versions

UCL Discovery